Compare Tango Therapeutics Inc. (TNGX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vale SA — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vale SA trades at $13.19 (market cap $57.30B). The key difference: Vale SA is far larger — about 15.3× Tango Therapeutics Inc.'s market cap, and Vale SA pays a 8.9% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vale SA for 110 Days on average.
| TNGX | VALE | |
|---|---|---|
Market Cap | $3.75B | $57.30B |
Volume | 9,619,106 | 25,010,417 |
Sector | Health | Basic Materials |
52-Week High | $32.90 | $17.82 |
52-Week Low | $7.50 | $11.10 |
Typical Hold Time | 0 Days | 110 Days |
Enterprise Value | $2.77B | $73.54B |
Dividend Yield | — | 8.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VALE trades at $13.21, down 2.29% today, with a bearish technical signal and three consecutive quarterly EPS misses. The stock shows mixed fundamentals with a P/E of 26.74 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from US steel expansion plans and rising operational costs.
Analyst consensus is cautious with 57% hold ratings and a $15.93 price target, suggesting 21% upside. Key risks include iron ore price volatility, Brazilian regulatory exposure, and margin compression from cost inflation. The base metals segment growth provides some diversification support amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
